Recurrent Gastrointestinal Carcinoid Tumor Completed Phase 2 Trials for Bevacizumab (DB00112)
Indication | Status | Phase |
---|---|---|
DBCOND0028801 (Recurrent Gastrointestinal Carcinoid Tumor) | Completed | 2 |
clinicaltrials.gov Identifier | Title | Purpose | Drugs |
---|---|---|---|
NCT00055809 | Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors | Treatment |